Lamivudine and Hepatitis B Reactivation
Authors: Rohit Loomba, Frank Pucino, Gyorgy Csako
Journal: Annals of Internal Medicine (2009)

Letters21 July 2009Lamivudine and Hepatitis B ReactivationRohit Loomba, MD, MHSc, Frank Pucino, PharmD, and Gyorgy Csako, MDRohit Loomba, MD, MHScFrom University of California, San Diego, La Jolla, CA 92093, and National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.Search for more papers by this author, Frank Pucino, PharmDFrom University of California, San Diego, La Jolla, CA 92093, and National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.Search for more papers by this author, and Gyorgy Csako, MDFrom University of California, San Diego, La Jolla, CA 92093, and National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-2-200907210-00015 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:We thank Dr. Hsu and colleagues for their comments on our meta-analysis. We agree that corticosteroids play an important role in chemotherapy-induced HBV reactivation, which is why we listed corticosteroid use in a dedicated column in Table 1 of our article. Unfortunately, as apparent from the adjacent chemotherapy column showing administration of CHOP (cyclophosphamide, hydroxydaunomycin, Oncovin [vincristine], and prednisone), patients in the studies by Lau and colleagues (1) and Hsu and associates (2) were both erroneously labeled as not receiving corticosteroids and not reporting corticosteroid use, respectively. We also acknowledge that, instead of being listed as a randomized ...References1. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742-9. [PMID: 14724827] CrossrefMedlineGoogle Scholar2. Hsu CHC, Su IJ, Hwang WS, Wang MC, Lin SF, Lin TH, et al. A prospective comparative study of prophylactic or therapeutic use of lamivudine for chemotherapy-associated hepatitis B (HBV) reactivation in non-Hodgkin's lymphoma patients [Abstract]. Gastroenterology. 2006;131:S297, 788. Google Scholar3. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, Lin SF, et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology. 2008;47:844-53. [PMID: 18302293] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of California, San Diego, La Jolla, CA 92093, and National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, MD 20892.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSystematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy Rohit Loomba , Ayana Rowley , Robert Wesley , T. Jake Liang , Jay H. Hoofnagle , Frank Pucino , and Gyorgy Csako Lamivudine and Hepatitis B Reactivation Chiun Hsu , Ann-Lii Cheng , and Pei-Jer Chen Metrics 21 July 2009Volume 151, Issue 2Page: 141-142KeywordsChemotherapyClinical trial reportingClinical trialsConflicts of interestCyclophosphamideHepatitis AHepatitis BProphylaxis ePublished: 21 July 2009 Issue Published: 21 July 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...